About 64x Bio
64x Bio is a company based in San Francisco (United States) founded in 2017 by David Thompson, Pamela Silver, Jeff Way, and George M Church.. 64x Bio has raised $59.65 million across 3 funding rounds from investors including Lifeforce Capital, Northpond Ventures and Michael Chambers. The company has 18 employees as of December 31, 2022. 64x Bio offers products and services including End-to-End Platform. 64x Bio operates in a competitive market with competitors including Senti Biosciences, Poseida Therapeutics, ADARx Pharmaceuticals, CRISPR Therapeutics and Aldevron, among others.
- Headquarter San Francisco, United States
- Employees 18 as on 31 Dec, 2022
- Founders David Thompson, Pamela Silver, Jeff Way, George M Church
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$59.65 M (USD)
in 3 rounds
-
Latest Funding Round
$55 M (USD), Series A
Jan 19, 2022
-
Investors
Lifeforce Capital
& 12 more
-
Employee Count
18
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of 64x Bio
64x Bio offers a comprehensive portfolio of products and services, including End-to-End Platform. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Platform for designing scalable therapeutic systems efficiently.
Unlock access to complete
Unlock access to complete
Funding Insights of 64x Bio
64x Bio has successfully raised a total of $59.65M across 3 strategic funding rounds. The most recent funding activity was a Series A round of $55 million completed in January 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 3
- Last Round Series A — $55.0M
-
First Round
First Round
(01 Jun 2018)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jan, 2022 | Amount | Series A - 64x Bio | Valuation | Lifeforce Capital | |
| Nov, 2020 | Amount | Seed - 64x Bio | Valuation | Refactor Capital , First Round Capital |
|
| Jun, 2018 | Amount | Seed - 64x Bio | Valuation | Y Combinator |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in 64x Bio
64x Bio has secured backing from 13 investors, including venture fund and angel investors. Prominent investors backing the company include Lifeforce Capital, Northpond Ventures and Michael Chambers. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm focused on healthcare startups
|
Founded Year | Domain | Location | |
|
Venture capital firm investing in life sciences & tech sectors
|
Founded Year | Domain | Location | |
|
Future Ventures is focused on early-stage venture capital investments.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by 64x Bio
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - 64x Bio
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
64X Bio Comparisons
Competitors of 64x Bio
64x Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Senti Biosciences, Poseida Therapeutics, ADARx Pharmaceuticals, CRISPR Therapeutics and Aldevron, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cell-based therapies for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| domain | founded_year | HQ Location |
Developer of genetic therapeutic solutions to edit single point mutations on RNA transcripts
|
|
| domain | founded_year | HQ Location |
Solutions for genetic diseases are developed using CRISPR-Cas9 genome editing.
|
|
| domain | founded_year | HQ Location |
Developer and custom manufacturer of nucleic acids, proteins and antibodies for research, clinical and commercial applications
|
|
| domain | founded_year | HQ Location |
Therapeutics for molecular-level cancer treatment are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Frequently Asked Questions about 64x Bio
When was 64x Bio founded?
64x Bio was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is 64x Bio located?
64x Bio is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is 64x Bio a funded company?
64x Bio is a funded company, having raised a total of $59.65M across 3 funding rounds to date. The company's 1st funding round was a Seed of $150K, raised on Jun 01, 2018.
How many employees does 64x Bio have?
As of Dec 31, 2022, the latest employee count at 64x Bio is 18.
What does 64x Bio do?
64x Bio was founded in 2017 in San Francisco, United States, within the biotechnology sector. Focus is placed on cell and gene therapy development for various disease treatments. A VectorSelect platform is utilized, incorporating DNA library synthesis, next-generation sequencing, and machine learning to design cells for biomanufacturing and therapeutic uses. Genome manipulation is employed to reprogram and edit DNA in organisms.
Who are the top competitors of 64x Bio?
64x Bio's top competitors include CRISPR Therapeutics, Senti Biosciences and Poseida Therapeutics.
What products or services does 64x Bio offer?
64x Bio offers End-to-End Platform.
Who are 64x Bio's investors?
64x Bio has 13 investors. Key investors include Lifeforce Capital, Northpond Ventures, Michael Chambers, Future Ventures, and First Round Capital.